Fatty acid synthase: A metabolic oncogene in prostate cancer?

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 47-53

  Baron, Antonella ^a   Migita, Toshiro ^a   Tang, Dan ^a   Loda, Massimo ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fatty acid synthase; Metabolism; Prostate cancer

Indexed keywords

FATTY ACID SYNTHASE; ENZYME INHIBITOR; LIPID MOBILIZER HORMONE; OXYGEN; PEPTIDE;

APOPTOSIS; CANCER CELL; CELL PROLIFERATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GLYCOLYSIS; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR;

APOPTOSIS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MALE; OXYGEN; PEPTIDES; PROSTATIC NEOPLASMS;

EID: 2542445809     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10708     Document Type: Review

References (67)

1. Ayton P, Sneddon SF, Palmer DB, Rosewell IR, Owen MJ, Young B, Presley R, Subramanian V. 2001. Truncation of the Mll gene in exon 5 by gene targeting leads to early preimplantation lethality of homozygous embryos. Genesis 30:201-212.
2. Bull JH, Ellison G, Patel A, Muir G, Walker M, Underwood M, Khan F, Paskins L. 2001. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84:1512-1519.
3. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106.
4. Chirala SS, Chang H, Matzuk M, Abu-Elheiga L, Mao J, Mahon K, Finegold M, Wakil SJ. 2003. Fatty acid synthesis is essential in embryonic development: Fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 100:6358-6363.
5. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
6. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP, Korsmeyer SJ. 2003. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952-956.
7. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. 2003. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799-3804.
8. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC. 2003. Curcumin (Diferuloyl-Methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2:95-103.
9. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
10. Downward J. 2003. Cell biology: Metabolism meets death. Nature 424:896-897.
11. Egner R, Thumm M, Straub M, Simeon A, Schuller HJ, Wolf DH. 1993. Tracing intracellular proteolytic pathways. Proteolysis of fatty acid synthase and other cytoplasmic proteins in the yeast Saccharomyces cerevisiae. J Biol Chem 268:27269-27276.
12. Epstein JI, Carmichael M, Partin AW. 1995. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86.
13. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. 1993. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571-1579.
14. Hannun YA, Obeid LM. 2002. The ceramide-centric universe of lipid-mediated cell regulation: Stress encounters of the lipid kind. J Biol Chem 277:25847-25850.
15. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV. 2001. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15:1817-1828.
16. Heiligtag SJ, Bredehorst R, David KA. 2002. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 9:1017-1025.
17. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. 2002. Going malignant: The hypoxia-cancer connection in the prostate. Bioessays 24:749-757.
18. Hyltander A, Drott C, Korner U, Sandstrom R, Lundholm K. 1991. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 27:9-15.
19. Igbavboa U, Hamilton J, Kim HY, Sun GY, Wood WG. 2002. A new role for apolipoprotein E: Modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J Neurochem 80:255-261.
20. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR. 2001. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397-1404.
21. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. 2003. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55:219-237.
22. Kasumov T, Martini WZ, Reszko AE, Bian F, Pierce BA, David F, Roe CR, Brunengraber H. 2002. Assay of the concentration and (13)C isotopic enrichment of propionyl-CoA, methylmalonyl-CoA, and succinyl-CoA by gas chromatography-mass spectrometry. Anal Biochem 305: 90-96.
23. Kuhajda FP. 2000. Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition 16:202-208.
24. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. 2003. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63:132-139.
25. Legaspi A, Jeevanandam M, Starnes HF, Jr., Brennan MF. 1987. Whole body lipid and energy metabolism in the cancer patient. Metabolism 36:958-963.
26. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer ES. 2001. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61:1493-1499.
27. Lin Y, Salem N, Jr. 2002. A technique for the in vivo study of multiple stable isotope-labeled essential fatty acids. Prostaglandins Leukot Essent Fatty Acids 67:141-146.
28. Lomnitski L, Oron L, Sklan D, Michaelson DM. 1999. Distinct alterations in phospholipid metabolism in brains of apolipoprotein E-deficient mice. J Neurosci Res 58: 586-592.
29. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. 2002. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 62:2220-2226.
30. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. 2003. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 100:7841-7846.
31. McCue BA, Cason MM, Curtis MA, Faulkner RD, Dahlin DC. 2002. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. J Pharm Biomed Anal 28:199-208.
32. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. 1999. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high GIeason score and advanced stage. Cancer Res 59:4291-4296.
33. Medes G, Thomas A, Weinhouse S. 1953. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 13:27-29.
34. Myers RB, Oelschlager DK, Weiss HL, Frost AR, Grizzle WE. 2001. Fatty acid synthase: An early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 165:1027-1032.
35. Nesterov A, Ivashchenko Y, Kraft AS. 2002. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21:1135-1140.
36. Ng CP, Zisman A, Bonavida B. 2002. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of XIAP in resistance. Prostate 53: 286-299.
37. Ookhtens M, Kannan R, Lyon I, Baker N. 1984. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 247:R146-R153.
38. Paulauskis JD, Sul HS. 1989. Hormonal regulation of mouse fatty acid synthase gene transcription in liver. J Biol Chem 264:574-577.
39. Pflug BR, Pecher SM, Brink AW, Nelson JB, Foster BA. 2003. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 58:1-9.
40. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. 1996a. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745-2747.
41. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. 1996b. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189-1193.
42. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF. 1998. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58:4611-4615.
43. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP. 2000. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213-218.
44. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. 2001. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 47:102-110.
45. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. 2003. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707-715.
46. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. 2002. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287:1662-1670.
47. Russell ST, Tisdale MJ. 2002. Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br J Cancer 87:580-584.
48. Sabine JR, Abraham S. 1967. Control of lipid metabolism in hepatomas: Insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer Res 27(4):793-799.
49. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. 1998. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop. Leukemia 12:840-844.
50. Shurbaji MS, Kalbfleisch JH, Thurmond TS. 1996. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27:917-921.
51. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. 2000. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925.
52. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. 1997. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086-1090.
53. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, Verhoeven G. 2000. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88:176-179.
54. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G. 2002. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22.
55. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G. 2003. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302:898-903.
56. Tamatani T, Hattori K, Nakashiro K, Hayashi Y, Wu S, Klumpp D, Reddy JK, Oyasu R. 1999. Neoplastic conversion of human urothelial cells in vitro by overexpression of H2O2-generating peroxisomal fatty acyl CoA oxidase. Int J Oncol 15:743-749.
57. Thupari JN, Pinn ML, Kuhajda FP. 2001. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285: 217-223.
58. Usui S, Suzuki K, Yamanaka H, Nakano T, Nakajima K, Hara Y, Okazaki M. 2002. Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clin Chim Acta 317:133-143.
59. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. 2002. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642-646.
60. Vizirianakis IS, Pappas IS, Gougoumas D, Tsiftsoglou AS. 1999. Expression of ribosomal protein S5 cloned gene during differentiation and apoptosis in murine erythroleukemia (MEL) cells. Oncol Res 11:409-419.
61. Voinov VG, Van den Heuvel H, Claeys M. 2002. Resonant electron capture mass spectrometry of free fatty acids: Examination of ion structures using deuterium-labeled fatty acids and collisional activation. J Mass Spectrom 37:313-321.
62. Wanders RJ, Vreken P, Ferdinandusse S, Jansen GA, Waterham HR, van Roermund CW, Van Grunsven EG. 2001. Peroxisomal fatty acid alpha- and beta-oxidation in humans: Enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem Soc Trans 29: 250-267.
63. Warberg O. 1956. On the origin of cancer cells. Science 123:309-314.
64. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Korber E, Kolb HJ. 1986. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler 367:905-912.
65. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Jr., Hampton GM. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-5978.
66. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES. 2002. Activation of fatty acid synthesis during neoplastic transformation: Role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279: 80-90.
67. Zhang L, Joshi AK, Smith S. 2003. Cloning, expression, characterization and interaction of two components of a human mitochondrial fatty acid synthase: Malonyl transferase and acyl carrier protein. J Biol Chem, in press.